Belite plans filing for oral Stargardt drug after phase 3 win
Belite Bio has said the results of the DRAGON trial of its oral therapy for sight-robbing disorder Stargardt disease type 1 (STGD1), tinlarebant, could support an FDA filing. The San Diego biotech said that DRAGON is the first successful pivotal trial in patients with STGD1, an eye disease that leads to progressive vision loss, usually…